Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

CIML-NK Cells

"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER